Physician profile
Darrick Sealey
NPI 1750053401
$16,683.52
in general payments reported to CMS, 2019-2025
25 companies · $5,094 in 2025
The $5,094 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $721 · 2022: $3,156 · 2023: $3,866 · 2024: $3,847 · 2025: $5,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,794.21 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,101.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,012.91 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,856.44 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,663.65 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,327.16 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,197.41 | 2021-2025 | |
| Lundbeck LLC | $1,051.18 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $828.71 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $618.38 | 2022-2024 | Jornay Pm |
| Corium, LLC | $610.15 | 2021-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $589.79 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $421.85 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $417.53 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $397.69 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $340.47 | 2024-2025 | Dyanavel Xr, Onyda Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $221.47 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $200.63 | 2021-2025 | Adzenys Xr-Odt, Exxua |
| Idorsia Pharmaceuticals US INC | $176.33 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $164.83 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $145.52 | 2023-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $129.69 | 2022 | |
| Bausch Health US, LLC | $94.21 | 2022-2023 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $81.88 | 2022 | |
| Brainsway USA INC | $17.38 | 2025 | Deep Tms System |
| Eisai INC. | $17.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrick Sealey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.